THE BOTTOM LINE: A tax benefit, an acquisition and price hikes that boosted drug revenue helped Amgen, the world's biggest maker of biologic drugs, increase fourth-quarter profit by 30 percent.
THE NUMBERS: Net income was $1.02 billion, while adjusted profit was $1.39 billion, or $1.82 per share — 13 cents more than analysts expected. Revenue totaled $5.01 billion, up 13 percent.
THE FUTURE: Amgen forecast 2014 adjusted earnings per share of $7.90 to $8.20, disappointing investors and sending shares down 1 percent in after-hours trading. However, the company has some promising drugs in late testing.